Checking the Overall Picture for Exelixis, Inc. (EXEL)

Francis Harris
May 4, 2017

Head to IBD Industry Themes for more on Exelixis and other strong contenders during this first-quarter earnings season. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. Cowen and Company reissued an "outperform" rating on shares of Exelixis in a research note on Tuesday, January 24th. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. The share price of the stock plunged -16.59% for the year. For the last period, the company reported quarter over quarter EPS growth of 166.70% and quarter over quarter sales growth of 683.80%.

11/03/2016 - Deutsche Bank began new coverage on Exelixis, Inc. giving the company a " rating.

(EXEL). A frequently used tool among technical stock analysts is the moving average.

Exelixis, Inc. (EXEL)'s distance from 200 day simple moving average is 44.11 percent, its distance from 50 day simple moving average is 7.11 percent, while its distance from 20 day simple moving average is 8.8 percent. They set a "buy" rating and a $28.00 price objective for the company.

Exelixis, Inc. (EXEL) traded with the volume of 4.77 Million shares while its average 3 months volume is at 4470 shares. Wall Street analysts, on average, were anticipating just $65.23 million for the quarter.


If we look at stock performance in last active day trading, we see that stock has moved gained 2.04% to end the day at $146.58. "(EXEL) Lowered to Hold at Zacks Investment Research" was originally published by Transcript Daily and is the sole property of of Transcript Daily. The business's revenue for the quarter was up 425.3% compared to the same quarter past year. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Vincent T. Marchesi sold 10,000 shares of Exelixis stock in a transaction that occurred on Monday, April 3rd.

In other Exelixis news, Director Jack L. Wyszomierski sold 5,150 shares of Exelixis stock in a transaction that occurred on Friday, March 31st.

02/28/2017 - Exelixis, Inc. had its " rating reiterated by analysts at William Blair. The shares were sold at an average price of $21.30, for a total transaction of $213,000.00. At the time of writing in early-afternoon trading, shares of Exelixis are flat at $23.15. They issued a "market perform" rating for the company. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & worldwide trademark and copyright law. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". The disclosure for this sale can be found here. (EXEL) has an Average Brokerage Recommendation (ABR) of 1.63, according to data compiled by Zacks Investment Research. Laurion Capital Management LP acquired a new stake in Exelixis during the third quarter worth approximately $208,000. Insiders sold 393,071 shares of company stock valued at $8,784,085 over the last quarter. KCG Holdings Inc. now owns 130,582 shares of the biotechnology company's stock valued at $1,670,000 after buying an additional 2,780 shares during the last quarter.

"The Exelixis team's progress this quarter is a launching point from which to build throughout 2017 as we work diligently to position the company as a sustainable business focused on improving the treatment of cancer for patients on a global basis", said the company's President and Chief Executive Officer, Michael M. Morrissey, Ph.D.

Other reports by TheDigitalNewspaper

Discuss This Article

FOLLOW OUR NEWSPAPER